Clinical Trials Browser

INDUSTRY × Etoposide × 90 days × Clear all

Small Cell Lung Carcinoma

Neuroendocrine Neoplasms

Extrapulmonary Neuroendocrine Cancer

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

Small Cell Lung Cancer Extensive Stage

Leukemia, Myeloid, Acute

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Small Cell Lung Carcinoma

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Leukemia, Myeloid, Acute

Recurrence, Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Extensive Stage Small Cell Lung Cancer

Leukemia, Myeloid, Acute

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Advanced Solid Tumors

SCLC,Extensive Stage

Small Cell Lung Carcinoma

Recurrence, Leukemia, Myeloid, Acute

Extensive Stage Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Bites and Stings, Lung Neoplasms

Clinical Trials

DAREONᵀᴹ-8

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

MK 7339-013

MK-6070-003

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

TROPION-Lung12

DeLLphi-312

SEZanne

MK-7339-012

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

OLYMPIA-4

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

SKB500 Combinations in Patients With Small Cell Lung Cancer

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

iMATRIX GLO

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

TAZMAN

CASPIAN

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

SKYSCRAPER-02

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

SYS6090 Combination Therapy in Advanced Lung Cancer

IMforte

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)